NCT06004336View on ClinicalTrials.gov

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

PHASE2RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2029

Conditions
Oligometastatic Renal Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Given by vein (IV)

RADIATION

Radiation therapy

Given by vein (IV)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Cancer Prevention Research Institute of Texas

OTHER

lead

M.D. Anderson Cancer Center

OTHER